{"id":"https://openalex.org/W2554557808","doi":null,"title":"Molecular Modeling Based, Design Synthesis and Cytotoxic Activity of Substituted Arylidene Piperazinoquinoline, a Hybrid Pharmacophore, Targeting Epidermal Growth Factor Receptor (EGFR),","display_name":"Molecular Modeling Based, Design Synthesis and Cytotoxic Activity of Substituted Arylidene Piperazinoquinoline, a Hybrid Pharmacophore, Targeting Epidermal Growth Factor Receptor (EGFR),","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W2554557808","mag":"2554557808"},"language":"en","primary_location":{"id":"mag:2554557808","doi":null,"is_oa":false,"landing_page_url":"http://www.lifesciencesite.com/lsj/life0803/044_6328life0803_257_265.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2554557808"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059923219","display_name":"Enayat Ibrahim Aly","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Enayat Ibrahim Aly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5059923219"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.8119999766349792,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.8119999766349792,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T14099","display_name":"Synthesis and Characterization of Heterocyclic Compounds","score":0.15109999477863312,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.02199999988079071,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8009999990463257},{"id":"https://openalex.org/keywords/hybrid-pharmacophore","display_name":"hybrid pharmacophore","score":0.8949999809265137},{"id":"https://openalex.org/keywords/molecular-hybridization","display_name":"molecular hybridization","score":0.8489999771118164},{"id":"https://openalex.org/keywords/virtual-screening","display_name":"virtual screening","score":0.8259999752044678},{"id":"https://openalex.org/keywords/mcf-7-cells","display_name":"MCF-7 cells","score":0.859000027179718},{"id":"https://openalex.org/keywords/cytotoxicity","display_name":"cytotoxicity","score":0.8980000019073486},{"id":"https://openalex.org/keywords/anti-breast-cancer-agents","display_name":"anti-breast cancer agents","score":0.7329999804496765},{"id":"https://openalex.org/keywords/7-chloroquinoline","display_name":"7-chloroquinoline","score":0.7419999837875366},{"id":"https://openalex.org/keywords/atp-binding-site","display_name":"ATP binding site","score":0.6499999761581421}],"concepts":[{"id":"https://openalex.org/C56173144","wikidata":"https://www.wikidata.org/wiki/Q1539893","display_name":"Pharmacophore","level":2,"score":0.8401938676834106},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.7054593563079834},{"id":"https://openalex.org/C2776201271","wikidata":"https://www.wikidata.org/wiki/Q409292","display_name":"Piperazine","level":2,"score":0.6014180183410645},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5447233319282532},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.5405307412147522},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.46732819080352783},{"id":"https://openalex.org/C103697762","wikidata":"https://www.wikidata.org/wiki/Q4112105","display_name":"Virtual screening","level":3,"score":0.46472862362861633},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.44929683208465576},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.42146602272987366},{"id":"https://openalex.org/C41685203","wikidata":"https://www.wikidata.org/wiki/Q1974042","display_name":"Docking (animal)","level":2,"score":0.42115771770477295},{"id":"https://openalex.org/C2777506169","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"EGFR inhibitors","level":4,"score":0.42044180631637573},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4177708327770233},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4144090712070465},{"id":"https://openalex.org/C2776362946","wikidata":"https://www.wikidata.org/wiki/Q424374","display_name":"Epidermal growth factor","level":3,"score":0.4140758514404297},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.36044639348983765},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.34185153245925903},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3163323700428009},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2702493965625763},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.19005486369132996},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.13288837671279907},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.06595116853713989},{"id":"https://openalex.org/C159110408","wikidata":"https://www.wikidata.org/wiki/Q121176","display_name":"Nursing","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2554557808","doi":null,"is_oa":false,"landing_page_url":"http://www.lifesciencesite.com/lsj/life0803/044_6328life0803_257_265.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8560000061988831,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1592483428","https://openalex.org/W1973856448","https://openalex.org/W1980547595","https://openalex.org/W1984226397","https://openalex.org/W1985421974","https://openalex.org/W1988345806","https://openalex.org/W1994928998","https://openalex.org/W1995677244","https://openalex.org/W2006800300","https://openalex.org/W2021861168","https://openalex.org/W2055904567","https://openalex.org/W2071959246","https://openalex.org/W2073390975","https://openalex.org/W2088000382","https://openalex.org/W2096495250","https://openalex.org/W2099072746","https://openalex.org/W2109689528","https://openalex.org/W2121356423","https://openalex.org/W2128307445"],"related_works":["https://openalex.org/W2073561941","https://openalex.org/W2183656655","https://openalex.org/W7127604030","https://openalex.org/W2948648471","https://openalex.org/W1994928998","https://openalex.org/W2063130697","https://openalex.org/W4411147317","https://openalex.org/W4408481017","https://openalex.org/W6920963685","https://openalex.org/W2337170247"],"abstract_inverted_index":{"A":[0],"series":[1],"of":[2,34,76,122,126],"1-(2-(4-substitutedarylidene)":[3],"hydrazinyl-4-(7-chloroquinolin-4-yl)":[4],"piperazine-2,":[5],"5-dione":[6],"VI":[7],"was":[8,21],"designed":[9,27],"by":[10],"molecular":[11],"hybridization":[12],"approach":[13],"and":[14,131],"synthesized":[15],"for":[16,58,119],"biological":[17],"evaluation.":[18],"Virtual":[19],"screening":[20],"carried":[22],"out":[23],"through":[24],"docking":[25],"the":[26,30,50,54,69,77,83,89,100,104,116],"compounds":[28,44,55,78,90],"into":[29],"ATP":[31],"binding":[32,47],"site":[33],"epidermal":[35],"growth":[36],"factor":[37],"receptor":[38],"(EGFR)":[39],"to":[40],"predict":[41],"if":[42],"these":[43],"have":[45],"similar":[46],"mode":[48],"as":[49,99,115],"EGFR":[51,70,127],"inhibitors.":[52],"Subsequently,":[53],"were":[56,79],"examined":[57],"their":[59],"cytotoxic":[60],"effect":[61],"on":[62,82],"human":[63],"breast":[64,84],"cell-line":[65],"(MCF-7)":[66],"in":[67],"which":[68],"is":[71],"highly":[72],"expressed.":[73],"Although":[74],"most":[75,101],"quite":[80],"effective":[81],"cancer":[85,133],"cell":[86],"line":[87],"examined,":[88],"II,":[91],"III,":[92],"IV":[93],"a,":[94],"IVc,":[95],"VIa,":[96],"VIc":[97],"emerged":[98],"active":[102],"among":[103],"prepared":[105],"series.":[106],"Thus":[107],"7-chloro-4-":[108],"(2,":[109],"5-dioxo":[110],"4-substitutedarylidene":[111],"piperazinoquinoline":[112],"can":[113],"serve":[114],"prototype":[117],"molecule":[118],"further":[120],"development":[121],"a":[123],"new":[124],"class":[125],"Tyrosine":[128],"Kinase":[129],"inhibitors":[130],"anti-breast":[132],"agents.":[134]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2554557808","counts_by_year":[{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-11-30T00:00:00"}
